They have changed registered office because they EXPECT an asset SALE and then RE FOCUS business into a FRESH start !!
, Modern Water will devote its management time and effort to its restructured innovative Membrane Processes Division.
The Company confirms that negotiations for the sale of the assets of Modern Water Inc., the US-based Monitoring Division, are ongoing and further updates will be issued as soon as there are any material developments.
A successful sale of the Monitoring Division would result in a significant strengthening of the Group's balance sheet and provide a solid base on which to support a more focused and efficient Membrane Processes Division, in which there is an encouraging pipeline of international development projects.
• £2mln placing July 2019 for US FDA trials etc. AMP selling and had 15% (18mln) since they have committed their stake as guarantee for loan due 30th Sept. • The lenders who acquired the AMP shares have clearly sold them all at 13p on Tuesday 8th Oct as they believe AMP ( rightly) are going bust • Large 2.9mln (£650k) buy late 8th October 2019 • Enrolment for the Clinical Trials has now passed 98% in the lung transplant pathway and 87% in the lung lobe resection pathway, with a total of 80 patients targeted for enrolment • We have now entered a crucial period for the Company as the Clinical Trials near completion, with the top-line results of the Clinical Trials expected before the end of 2019 • 40 clinical trials currently ongoing into the use of 129Xe MRI accruing to the FDA website. • The burden of pulmonary disease in the USA is approximately US$150bn, with pulmonary disease widespread and growing, affecting nearly 40 million Americans • our unique medical drug-device combination utilizing 129Xe offers the ideal solution for improving pulmonary disease diagnosis and we are confident that this will be borne out during the Company's Clinical Trials.
#BRY Brady • Fallen 58p to 4p in 6 weeks since the accountants on 21st August and 23rd Sept and 26th Sept • Market cap £3mln 83mln shares in issue • Recurring revenues £7.8mln for H1 which contributed 82% of total sales • Cash June 2019 £1.9mln + bank overdraft • Cash outflow £1.1mln H1 2019 • Announced at 28p that it needed short term cash of £1.9mln by end of Nov 2019
uncement by the Bicycle therapeutics that the presentation at the ESMO 2019 Annual Congress of updated data from the Phase I / IIa trial evaluating BT1718 in patients with advanced solid tumors
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology firm pioneering a new therapeutic class based on its proprietary bicyclic peptide (Bicycles ®) product platform, announced today the introduction of updated information from a Phase I / IIa trial in cooperation with Cancer Research UK as well as the evaluation of BT1718 in an unselected group of sophisticated solid tumor patients. The findings will be submitted today at a poster session at the European Society of Medical Oncology (ESMO) 2019 Annual Congress in Barcelona, Spain, from 12:00-13:00 CET by Natalie Cook, Ph.D., a research researcher and senior clinical lecturer at the University of Manchester.
Patients were assessed for anti-tumor activity, safety and pharmacokinetics in the Phase I dose escalation up to the data cut-off of 7 August 2019. Based on data from patients in cohorts across dose levels tested, many of which are below the predicted therapeutic range, 13 of 24 evaluable patients (54%) had stable disease at the eight-week timepoint, including a patient who experienced a 45% reduction in a target lesion. Patients were assessed for anti-tumor activity, safety and pharmacokinetics in the Phase I dose escalation up to the data cut-off of 7 August 2019. BT1718 appeared to be tolerable with manageable adverse events with once-weekly dosing, which is the expected schedule for the Phase IIa portion of the study. BT1718 appeared to be tolerable with manageable adverse events with once-weekly dosing, which is the expected schedule for the Phase IIa portion of the study